在抗逆转录病毒治疗期间，P-糖蛋白基因型（MDR1 C3435T）对洛匹那韦和依非韦伦血浆水平无影响。
No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.
作者信息
Winzer Ralf, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B
机构信息
Medical Policlinic, Division of Infectious Diseases, University of Würzburg, Germany.
出版信息
Eur J Med Res. 2003 Dec 9;8(12):531-4.
BACKGROUND
In a retrospective study of HIV patients under antiretroviral therapy, we investigated the influence of the MDR1 genotype (C3435T) on plasma levels of lopinavir (LPV) and efavirenz (EFV).
METHODS
The MDR1 genotype was analysed from 67 patients who were treated with LPV (n = 32; mean treatment period 53 weeks) and/or EFV (n = 43, mean treatment period 105 weeks) between 1999 and 2003. Plasma levels of LPV (trough levels) and EFV (12-h-levels) were determined every three months. Data were analysed by the Kruskal-Wallis test.
RESULTS
There were no significant differences in the LPV and EFV plasma levels with respect to the MDR1 3435 genotype.
CONCLUSIONS
We did not find evidence for an influence of the MDR1 3435 genotype on plasma levels of LPV and EFV.
背景
在一项针对接受抗逆转录病毒治疗的HIV患者的回顾性研究中，我们调查了多药耐药基因1（MDR1）基因型（C3435T）对洛匹那韦（LPV）和依非韦伦（EFV）血浆水平的影响。
方法
分析了1999年至2003年间接受LPV治疗（n = 32；平均治疗期53周）和/或EFV治疗（n = 43，平均治疗期105周）的67例患者的MDR1基因型。每三个月测定一次LPV的血浆水平（谷浓度）和EFV的血浆水平（12小时浓度）。数据采用Kruskal-Wallis检验进行分析。
结果
LPV和EFV的血浆水平在MDR1 3435基因型方面无显著差异。
结论
我们未发现证据表明MDR1 3435基因型对LPV和EFV的血浆水平有影响。
Zotero 插件